DRG anticipates the next ten years to be a transitional time in the treatment of hemophilia A for patients with and without inhibitors. With the uptake of Roche / Chugai’s bispecific antibody Hemlibra and a diverse pipeline, both in terms of technology type and administration route, we forecast significant changes in disease management. The R&D emphasis has shifted to nonfactor treatment approaches to restore coagulation. Examples include Sanofi’s anti-ATIII siRNA, fitusiran, Novo Nordisk’s anti-TFPIMAb, concizumab, and BioMarin’s gene therapy, BMN 270. Despite novel nonfactor hemophilia agents forecast to launch, we expect the factor concentrate market to remain competitive, and the high demand for factor concentrates to persist.


  • How will physicians treating hemophilia A differentiate between the various emerging therapies, and which will gain the greatest market and patient share in an increasingly stringent regulatory environment?
  • What clinical roles will Hemlibra, fitusiran, concizumab, and gene therapy play in the evolving hemophilia A treatment landscape?
  • How will the management of patients with inhibitors change when new treatment options become available? How will Hemlibra’s head start on its competitors play out over the forecast period?
  • How will the factor VIII concentrate market evolve? How will nonfactor treatment options impact the multitude of brands vying for patient share in this space?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Findings
      • Hemophilia A +/- Inhibitors - Key Findings - December 2019
    • Key Updates
      • December 2019
      • September 2019
      • June 2019
    • Market Outlook
      • Key Findings
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Hemophilia A +/- Inhibitors?
        • What Factors Are Constraining the Market for Hemophilia A +/- Inhibitors?
      • Segment-Specific Trends
        • Hemophilia A
        • Hemophilia A + Inhibitors
    • Forecast
      • Market Forecast Assumptions - Hemophilia A - 2018-2028 - December 2019
      • Market Forecast Dashboard - Hemophilia A - 2018-2028 - December 2019
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
        • Etiology
      • Pathophysiology
        • Pathophysiology
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Prevalent Cases of Hemophilia A
        • Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
        • Drug-Treated Cases of Hemophilia A
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Recombinant Factor VIII
        • Bypass Agents
        • Substitutive Therapy
      • Medical Practice
        • Overview
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Hemophilia A
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Factor-Based Therapy
        • Hemostatic Rebalancing Therapy
        • Gene Therapy
      • Early-Phase Pipeline Analysis
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Hemophilia Bibliography

Author(s): Kerri Brown, M Pharm; Abey John, MPH

Kerri Brown, is an analyst with Decision Resources Group, focused on finding stories in data and developing products to inform strategic decisions in the hemophilia and diabetes spaces. Kerri holds a master of pharmacy degree from King’s College London with 1 st class honors. Prior to joining DRG, she was a national clinical educator at a UK diabetes start-up, and has extensive experience of diabetes medical devices. Kerri has worked at AstraZeneca, and as a pharmacist in a national psychiatric clinical trial center. In addition to her work at DRG, Kerri is a practicing pharmacist with extensive clinical experience of UK physician prescribing in diabetes.

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country. Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.

Related Reports

Hemophilia | Access & Reimbursement | Detailed, Expanded Analysis (US)

Hemophilia treatment is gradually consuming more U.S. payer budget dollars. The increasing cost of factor concentrate and the growing preference for prophylaxis treatment are key factors drivin...

View Details